SG Americas Securities LLC Sells 140,530 Shares of Recursion Pharmaceuticals, Inc. $RXRX

SG Americas Securities LLC cut its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 90.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,701 shares of the company’s stock after selling 140,530 shares during the period. SG Americas Securities LLC’s holdings in Recursion Pharmaceuticals were worth $72,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Norges Bank bought a new position in Recursion Pharmaceuticals during the 2nd quarter valued at about $16,040,000. Bank Pictet & Cie Europe AG bought a new position in Recursion Pharmaceuticals during the third quarter valued at approximately $7,954,000. Geode Capital Management LLC boosted its holdings in Recursion Pharmaceuticals by 20.7% in the second quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock worth $39,353,000 after purchasing an additional 1,332,428 shares during the last quarter. First Trust Advisors LP grew its position in Recursion Pharmaceuticals by 82.3% in the 2nd quarter. First Trust Advisors LP now owns 1,880,290 shares of the company’s stock worth $9,514,000 after purchasing an additional 848,791 shares during the period. Finally, Vestmark Advisory Solutions Inc. raised its stake in Recursion Pharmaceuticals by 89.6% during the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 1,339,139 shares of the company’s stock valued at $6,776,000 after buying an additional 632,900 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

RXRX has been the topic of a number of research reports. UBS Group set a $11.00 price target on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average target price of $9.40.

Insider Transactions at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 220,000 shares of the firm’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $4.36, for a total value of $959,200.00. Following the completion of the transaction, the director directly owned 6,649,863 shares of the company’s stock, valued at approximately $28,993,402.68. This trade represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Najat Khan sold 124,403 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total transaction of $548,617.23. Following the sale, the insider directly owned 611,135 shares in the company, valued at approximately $2,695,105.35. The trade was a 16.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 585,786 shares of company stock valued at $2,558,598 in the last ninety days. Corporate insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Stock Down 3.0%

Shares of RXRX stock opened at $4.19 on Friday. The company’s fifty day simple moving average is $4.50 and its two-hundred day simple moving average is $4.99. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The stock has a market cap of $2.18 billion, a P/E ratio of -2.33 and a beta of 0.95. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.02. The firm had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $19.36 million. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The business’s revenue was down 80.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.34) earnings per share. Analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.